作者
Michel A Missinou, Steffen Borrmann, Andreas Schindler, Saadou Issifou, Ayola A Adegnika, Pierre-Blaise Matsiegui, Ronald Binder, Bertrand Lell, Jochen Wiesner, Thomas Baranek, Hassan Jomaa, Peter G Kremsner
发表日期
2002/12/14
期刊
The Lancet
卷号
360
期号
9349
页码范围
1941-1942
出版商
Elsevier
简介
Safe and effective antimalarial drugs with new methods of action are urgently needed. Fosmidomycin inhibits the synthesis of isoprenoid by Plasmodium falciparum, and suppresses the growth of multidrug-resistant strains in vitro. Our aim was to assess the efficacy and tolerability of fosmidomycin in adults with malaria in Gabon. We administered the drug for 5, 4, or 3 days (1–2 g every 8 h), in nine, eight, and ten evaluable patients, respectively. All treatment regimens were well tolerated. Cure rates by day 14 were 89% (eight of nine), 88% (seven of eight), and 60% (six of ten), for treatment durations of 5, 4, and 3 days, respectively. These data suggest that fosmidomycin is a safe and effective treatment for uncomplicated malaria if given for 4 days or more.
引用总数
2003200420052006200720082009201020112012201320142015201620172018201920202021202220231529132337101215251219913674331073
学术搜索中的文章
MA Missinou, S Borrmann, A Schindler, S Issifou… - The Lancet, 2002